Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of HB0017 Injection to Investigate PK After Subcutaneous Administration at Different Injection Sites in Healthy Volunteers, and to Evaluate Its Safety, Tolerability, and Pharmacokinetics in Low-body-weight Healthy Subjects

NCT07920861 is registered in ClinicalTrials.gov with Huabo Biopharm Co., Ltd. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07920861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of HB0017 Injection to Investigate PK After Subcutaneous Administration at Different Injection Sites in Healthy Volunteers, and to Evaluate Its Safety, Tolerability, and Pharmacokinetics in Low-body-weight Healthy Subjects
Lead sponsor
Huabo Biopharm Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 19, 2026
Completion date
February 28, 2027
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis, psoriasis

Arms

As registered; 9 arms.

  • PART1: Group 1,75mg ExperimentalHB0017 Injection, HB0017 Placebo

    single-dose, SC, HB0017 75 mg or placebo

  • PART1: Group 2, 150mg ExperimentalHB0017 Injection, HB0017 Placebo

    single-dose, SC, HB0017 150 mg or placebo

  • PART1: Group 3, 300mg ExperimentalHB0017 Injection, HB0017 Placebo

    single-dose, SC, HB0017 300 mg or placebo

  • PART2: Group 4, 150mg, domen ExperimentalHB0017 Injection

    single-dose, SC at domen, HB0017 150 mg

  • PART2: Group 5, 150mg, upper arms ExperimentalHB0017 Injection

    single-dose, SC at upper arms, HB0017 150 mg

+4 more arms

Primary endpoints

Registered primary outcome measures; 3 primary.

  • Adverse events through study completion

    PART 1: Number of participants experiencing adverse events as assessed by CTCAE v5.0.

  • Cmax From pre-dosing to 140 days post-dosing

    PART 2:Cmax was the maximum observed plasma concentration directly observed from data. Data analysis by group across injection sites - abdomen, upper arm, thigh - at the same dose.

  • AUCinf From pre-dosing to 140 days post-dosing

    PART 2 : AUCinf was area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf , if data permits).Data analysis by group across injection sites - abdomen, upper arm, thigh - at the same dose.

Lead sponsor's other trials

Huabo Biopharm Co., Ltd., most recent start first.

Similar trials

Same condition (Spondylitis, Ankylosing) and phase, most recent start first.